Karyopharm Therapeutics Inc. (KPTI)
KPTI Stock Price Chart
Explore Karyopharm Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze KPTI price movements and trends.
KPTI Company Profile
Discover essential business fundamentals and corporate details for Karyopharm Therapeutics Inc. (KPTI) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Nov 2013
Employees
279.00
Website
https://www.karyopharm.comCEO
Richard A. Paulson
Description
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases. The company discovers, develops, and commercializes novel and Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1. Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma, and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company has license agreement with Menarini Group to develop and commercialize NEXPOVIO for human oncology indications in Europe, including the United Kingdom; Latin America; and other countries. Its oral SINE compounds also designed to force nuclear accumulation in the levels of multiple tumor suppressor and growth regulatory proteins. The company was incorporated in 2008 and is headquartered in Newton, Massachusetts.
KPTI Financial Timeline
Browse a chronological timeline of Karyopharm Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 May 2026
Upcoming earnings on 17 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$3.67, while revenue estimate is $39.56M.
Earnings released on 11 Aug 2025
EPS came in at -$4.32 falling short of the estimated -$3.80 by -13.68%, while revenue for the quarter reached $37.93M , missing expectations by -4.13%.
Earnings released on 12 May 2025
EPS came in at -$2.77 surpassing the estimated -$4.21 by +34.20%, while revenue for the quarter reached $30.02M , missing expectations by -14.54%.
Stock split effective on 26 Feb 2025
Shares were split 1 : 15 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Feb 2025
EPS came in at -$3.60 surpassing the estimated -$3.90 by +7.69%, while revenue for the quarter reached $30.54M , missing expectations by -19.26%.
Earnings released on 5 Nov 2024
EPS came in at -$3.90 surpassing the estimated -$4.05 by +3.70%, while revenue for the quarter reached $38.78M , beating expectations by +1.54%.
Earnings released on 6 Aug 2024
EPS came in at -$3.00 surpassing the estimated -$4.35 by +31.03%, while revenue for the quarter reached $42.79M , beating expectations by +18.26%.
Earnings released on 8 May 2024
EPS came in at -$4.80 surpassing the estimated -$4.95 by +3.03%, while revenue for the quarter reached $33.13M , missing expectations by -3.90%.
Earnings released on 29 Feb 2024
EPS came in at -$5.40 falling short of the estimated -$4.35 by -24.14%, while revenue for the quarter reached $33.75M , missing expectations by -4.67%.
Earnings released on 2 Nov 2023
EPS came in at -$4.50 falling short of the estimated -$4.20 by -7.14%, while revenue for the quarter reached $36.01M , missing expectations by -3.41%.
Earnings released on 2 Aug 2023
EPS came in at -$4.35 surpassing the estimated -$5.10 by +14.71%, while revenue for the quarter reached $37.58M , beating expectations by +4.36%.
Earnings released on 4 May 2023
EPS came in at -$4.50 surpassing the estimated -$5.10 by +11.76%, while revenue for the quarter reached $38.70M , beating expectations by +5.73%.
Earnings released on 15 Feb 2023
EPS came in at -$6.45 falling short of the estimated -$5.10 by -26.47%, while revenue for the quarter reached $33.58M , missing expectations by -2.46%.
Earnings released on 3 Nov 2022
EPS came in at -$6.75 surpassing the estimated -$8.40 by +19.64%, while revenue for the quarter reached $36.15M , beating expectations by +3.78%.
Earnings released on 4 Aug 2022
EPS came in at -$9.30 surpassing the estimated -$9.45 by +1.59%, while revenue for the quarter reached $39.68M , beating expectations by +10.33%.
Earnings released on 5 May 2022
EPS came in at -$7.95 surpassing the estimated -$9.45 by +15.87%, while revenue for the quarter reached $47.67M , beating expectations by +38.54%.
Earnings released on 8 Feb 2022
EPS came in at $6.90 surpassing the estimated -$6.00 by +215.00%, while revenue for the quarter reached $126.27M , beating expectations by +139.54%.
Earnings released on 3 Nov 2021
EPS came in at -$10.34 falling short of the estimated -$10.19 by -1.47%, while revenue for the quarter reached $37.69M , beating expectations by +46.08%.
Earnings released on 5 Aug 2021
EPS came in at -$10.64 surpassing the estimated -$10.79 by +1.39%, while revenue for the quarter reached $22.60M , meeting expectations.
Earnings released on 3 May 2021
EPS came in at -$11.54 falling short of the estimated -$10.49 by -10.01%, while revenue for the quarter reached $23.26M , missing expectations by -12.46%.
Earnings released on 11 Feb 2021
EPS came in at -$8.85 falling short of the estimated -$8.70 by -1.72%, while revenue for the quarter reached $35.10M , beating expectations by +28.24%.
Earnings released on 2 Nov 2020
EPS came in at -$10.94 matching the estimated -$10.94, while revenue for the quarter reached $21.33M , beating expectations by +1.39%.
KPTI Stock Performance
Access detailed KPTI performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.